Agnes Seyda, Ph.D.
About Agnes Seyda, Ph.D.
Agnes Seyda, Ph.D., is the Director of Pharmacodiagnostics Project Management at Bristol-Myers Squibb, with extensive experience in precision medicine and diagnostics.
Title
Agnes Seyda, Ph.D. holds the title of Director Pharmacodiagnostics Project Management. She is currently active in this role at Bristol-Myers Squibb in Princeton, NJ.
Company
Agnes Seyda, Ph.D. is currently working at Bristol-Myers Squibb (BMS) as Director, Precision Medicine and Companion Diagnostics in Summit, NJ. She transitioned to BMS following its acquisition of Celgene, where she also serves as Director Pharmacodiagnostics Project Management.
Previous Positions
Agnes Seyda, Ph.D. served as Director at Janssen Diagnostics, LLC in 2016 for two months. From 2013 to 2016, she was Associate Director at Janssen Diagnostics, LLC (formerly Veridex, LLC), an affiliate of Johnson & Johnson. She also worked as Operations Manager at Janssen Diagnostics from 2012 to 2013. Previously, she held roles at Advanced Technologies and Regenerative Medicine (ATRM), a Johnson & Johnson affiliate, as Project Leader/Staff Scientist (2009-2012), Senior Scientist (2006), and Scientist (2003) for nine years in Somerville, NJ. Additionally, she was a Research Assistant Professor at Rutgers University and New Jersey Center for Biomaterials from 2001 to 2003.
Education and Expertise
Agnes Seyda, Ph.D. earned her Ph.D. in Biochemistry from the University of Toronto between 1995 and 2000. She completed her B.S. in Biochemistry at McMaster University from 1991 to 1995. She further achieved her Project Management Professional (PMP) certification from the Project Management Institute in 2008 after 11 months of study.
Responsibilities at Celgene
In her role at Celgene, Agnes Seyda, Ph.D. leads digital health initiatives and oversees the development of Software as Medical Devices (SaMD) programs. She is a member of the Global Project Team, where she provides feedback on clinical trial design, focusing on biomarkers and diagnostics. She also oversees the design and validation of primary and secondary clinical trial endpoints, such as Minimal Residual Disease.